New Pill Doubles Survival Time for Pancreatic Cancer Patients

A breakthrough pill for pancreatic cancer patients has achieved what researchers once thought impossible, nearly doubling how long people survive with the disease.

Revolution Medicines announced results from a global clinical trial testing daraxonrasib, a once-daily pill targeting RAS mutations found in over 90% of pancreatic cancer cases. Patients taking the new drug lived a median of 13.2 months compared to 6.7 months for those on standard chemotherapy.

The drug tackles a genetic mutation that scientists spent decades trying to stop. RAS mutations cause cells to grow uncontrollably, driving tumor formation in most pancreatic cancer cases. For years, this target was labeled "undruggable" because no medication could effectively block it.

More than 60 medical centers worldwide participated in the trial, which tested the pill in patients whose cancer had spread beyond the pancreas and who had already received other treatments. The drug was generally well tolerated, with rash being the most common side effect along with mouth sores, diarrhea, and nausea.

Revolution Medicines will now submit their data to the FDA for approval. The treatment has already been selected for a special FDA program designed to fast-track therapies addressing urgent national health priorities.

The Ripple Effect

This breakthrough extends far beyond one medication. Daraxonrasib proves that RAS mutations can be targeted, opening the door for similar treatments across multiple cancer types where these mutations drive disease.

The success will likely accelerate research into other RAS inhibitors currently in development. Multiple clinical trials are already testing similar approaches in pancreatic cancer and other cancers driven by these mutations.

Dr. Anna Berkenblit, Chief Scientific Officer at the Pancreatic Cancer Action Network, called it "a real opportunity to bring new hope for people facing this disease: hope for more time with family, hope for better quality of life."

Patients interested in RAS-targeted treatments can request biomarker testing to determine if they carry these mutations. The Pancreatic Cancer Action Network offers free testing through their Know Your Tumor program for eligible patients and provides case managers to help navigate treatment options.

While this trial has closed to new patients, other studies targeting RAS mutations continue enrolling nationwide.

This victory against a once-impossible target proves that persistence in cancer research eventually pays off.